344-70-7

Basic information

• Product Name: 4-(acetylamino)-2-fluorobenzenesulfonyl chloride
• Synonyms: 4-(acetylamino)-2-fluorobenzenesulfonyl chloride
• CAS NO: 344-70-7
• Molecular Formula: C₈H₇ClFNO₃S
• Molecular Weight: 251.6624832
• Mol File: 344-70-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(acetylamino)-2-fluorobenzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(acetylamino)-2-fluorobenzenesulfonyl chloride(344-70-7)
• EPA Substance Registry System: 4-(acetylamino)-2-fluorobenzenesulfonyl chloride(344-70-7)

Safety Data

• Hazardous Substances Data: 344-70-7(Hazardous Substances Data)

Usage

General Description

4-(acetylamino)-2-fluorobenzenesulfonyl chloride is a chemical compound with the molecular formula C8H8ClFO3S. It is an acyl chloride derivative and is commonly used as a reagent in organic synthesis. 4-(acetylamino)-2-fluorobenzenesulfonyl chloride is structurally related to sulfonyl chlorides and has a fluoro substituent which makes it useful for modifying and labeling biomolecules. It is known for its ability to react with various nucleophiles, including amines and alcohols, to form amides and esters, respectively. Additionally, 4-(acetylamino)-2-fluorobenzenesulfonyl chloride has shown potential for use in pharmaceutical research and the development of new drugs due to its ability to inhibit enzymes and modify proteins.

Upstream product

• 351-28-0 N-(3-fluorophenyl)acetamide 
• 372-19-0 meta-fluoroaniline 

Downstream Products

• 654063-26-0 N-(3-fluoro-4-methylsulfamoylphenyl)acetamide 
• 1308254-63-8 4-amino-2-fluoro-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)benzenesulfonamide 
• 1331890-91-5 N-(3-fluoro-4-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)acetamide 

Relevant articles and documents

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series

Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure-activity relationship, allowing optimization of antiparasite activity, physicochemical parameters, and ADME properties. We identified compound 50 as an advanced lead with an improved anti-T. cruzi activity in vitro (IC50 = 0.079 μM) and an enhanced metabolic stability (human clearance = 0.41 mL/min/g) and opportunity for the oral route of administration. After tolerability assessment, 50 demonstrated a promising in vivo efficacy.

PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

-